术后加巴喷丁对鼻窦手术阿片类药物用量及疼痛控制的影响
本研究纳入2021至2022年单机构接受内镜鼻窦手术和/或鼻中隔成形术的102例患者,比较术后首日加用加巴喷丁与不加用者在术后第一周的阿片类药物用量及疼痛控制情况。多变量回归分析显示,加用加巴喷丁与术后第一周阿片类药物用量减少44%(从21.6 mg降至9.5 mg)相关,而两组疼痛严重程度及睡眠干扰改善相似。
要点
- 术后加用加巴喷丁与第一周阿片类药物用量减少44%(从21.6 mg降至9.5 mg)相关。
- 两组术后7天内疼痛严重程度及睡眠干扰改善相似。
- 加用加巴喷丁未损害疼痛控制。
核心结论
- 术后加巴喷丁有效减少术后第一周阿片类药物使用,且不损害疼痛控制。
研究设计与样本
- 单机构纳入2021至2022年接受内镜鼻窦手术和/或鼻中隔成形术的患者,共102例,加巴喷丁组与无加巴喷丁组各51例。
主要发现
- 控制重要基线人口学、临床及手术相关变量后,术后加用加巴喷丁与术后第一周阿片类药物消耗减少44%(从21.6 mg降至9.5 mg)相关(B = -9.54,95% C.I. = [-17.84, -1.24],p = 0.025)。
- 两组术后7天内疼痛严重程度和睡眠干扰改善相似(B = -1.59,95% C.I. = [-5.03, 1.84],p = 0.36)。
关键数值与推荐
- 所有患者术后使用氢可酮-对乙酰氨基酚镇痛;半数患者术后第一日额外处方加巴喷丁。
- 受试者在术后24小时和7天完成修订版美国疼痛学会患者结局问卷。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study investigates the impact of postoperative gabapentin on opioid consumption and pain control following endoscopic sinus surgery (ESS) and/or septoplasty. METHODS: Patients who underwent ESS and/or septoplasty at a single institution from 2021 to 2022 were enrolled. All patients received postoperative hydrocodone-acetaminophen for pain control. Half of the patients were also prescribed gabapentin for the first postoperative day in addition to hydrocodone-acetaminophen. Subjects completed the Revised American Pain Society Patient Outcome Questionnaire 24 h and 7 days after surgery. We conducted a multivariable regression analysis to assess opioid consumption and improvement in pain scores in the first week between gabapentin and non-gabapentin groups. RESULTS: A total of 102 subjects, 51 in each arm, were enrolled. The mean age was 52 years and 53% of participants were female. Controlling for important baseline demographic, clinical, and surgically related variables, the addition of postoperative gabapentin was associated with a 44% (9.5 mg from 21.6 mg) reduction in opioids consumed in the first postoperative week (B = -9.54, 95% C.I. = [-17.84, -1.24], p = 0.025). In addition, patients in both arms exhibited similar improvement in pain severity and sleep interference in the first 7 days (B = -1.59, 95% C.I. = [-5.03, 1.84], p = 0.36). CONCLUSION: To the best of our knowledge, this is the first study to investigate the impact of postoperative gabapentin on opioid consumption and pain control following ESS and/or septoplasty. Our analysis demonstrated that postoperative gabapentin effectively reduced opioid use during the first postoperative week without compromising pain control. LEVEL OF EVIDENCE: 3 Laryngoscope, 133:1065-1072, 2023.
引用
- Yang HH, Wu TJ, Suh JD, et al. Postoperative Gabapentin's Effect on Opioid Consumption and Pain Control Following Sinonasal Surgery. Laryngoscope. 2022. PMID: 35833722. doi:10.1002/lary.30282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。